Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: $XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xeris Biopharma Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xeris Biopharma Holdings's position in the market.
Xeris Biopharma reported a Q1 2024 total revenue of $40.6M, up 22% from Q1 2023, with full-year 2024 revenue guidance set at $175M-$200M. They ended Q1 with $87.4M in cash, closed licensing agreements for XeriJect® and XeriSol™ formulations, and announced a partnership with Beta Bionics. The company highlighted growth in product revenue, net revenue, and new technology partnerships.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a liquid stable glucagon product for use in bi-hormonal pump systems. This agreement marks a significant step towards bringing innovative diabetes management solutions to the market.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) will report its first quarter 2024 financial results on May 9, 2024. The company is dedicated to developing and commercializing innovative products across various therapies. A conference call and webcast will be held at 8:30 a.m. Eastern Time to discuss the financial and operational results.